<div id="readability-page-1"><p>Wolfe Research analyst Kalpit Patel maintained a Buy rating on Revolution Medicines yesterday and set a price target of $165.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Kalpit Patel has given his Buy rating due to a combination of factors tied to Revolution Medicines’ lead asset daraxon and its positioning in pancreatic cancer. He views the recent launch trajectory favorably, citing strong early demand signals from the expanded access program in second-line and later PDAC, and believes close engagement with the FDA supports a timely NDA filing and a realistic path to approval around FY26.</p> <p>Patel also highlights meaningful upside optionality if emerging first-line data allow the company to pursue a broader, potentially line-agnostic label, which could push the stock materially above his target price as competitors struggle to run viable head-to-head trials. While acknowledging higher operating expense guidance driven largely by non-cash stock-based compensation and increased R&amp;D and SG&amp;A, he concludes that the long-term revenue opportunity for daraxon and the strategic advantage in the RAS pathway justify a positive stance on the shares.</p> <p>In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $172.00 price target.</p> <p>RVMD’s price has also changed dramatically  for the past six months – from $61.380 to $151.070, which is a 146.12% increase.</p></div>

RVMD

SBIO

LABU

<p>Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality</p>

Tip Ranks

Revolution Medicines

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Piper Sandler Cos

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality